Single B or T-cell epitope-based DNA vaccine using modified vector induces specific immune response against hepadnavirus

Xu, Huanbin; Xu, Wei; Chu, Yiwei; Wang, Ying; Xiong, Sidong

doi:10.1016/j.imlet.2005.02.014

Cited by 4 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Single B and T cell epitope vaccines can provide effective approaches against a variety of pathogens and malignancies 21 – 24 . To investigate the efficacy of linear B cell epitope vaccines against SARS-CoV-2 infection, we selected five different linear epitopes, present at different locations in the Spike protein, which were considered to potentially able to elicit protective antibodies 25 – 27 .…”

Section: Resultsmentioning

confidence: 99%

A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection

et al. 2022

View full text Add to dashboard Cite

Understanding the mechanisms and impact of booster vaccinations are essential in the design and delivery of vaccination programs. Here we show that a three dose regimen of a synthetic peptide vaccine elicits an accruing CD8+ T cell response against one SARS-CoV-2 Spike epitope. We see protection against lethal SARS-CoV-2 infection in the K18-hACE2 transgenic mouse model in the absence of neutralizing antibodies, but two dose approaches are insufficient to confer protection. The third vaccine dose of the single T cell epitope peptide results in superior generation of effector-memory T cells and tissue-resident memory T cells, and these tertiary vaccine-specific CD8+ T cells are characterized by enhanced polyfunctional cytokine production. Moreover, fate mapping shows that a substantial fraction of the tertiary CD8+ effector-memory T cells develop from re-migrated tissue-resident memory T cells. Thus, repeated booster vaccinations quantitatively and qualitatively improve the CD8+ T cell response leading to protection against otherwise lethal SARS-CoV-2 infection.

show abstract

Section: Resultsmentioning

confidence: 99%

A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Cytotoxicity was determined by a 4 h 5l Cr release assay as described previously [56]. Briefly, spleen cells were harvested from PBS, C1-, C2-, C3-PDDV or 18K-PDDV immunized mice and resuspended at a concentration of 1 × 10 6 /ml in complete 1640 medium (containing 10% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin) containing 10 μg/ml C1-, C2-, C3-18K fusion peptide, 18K control peptide or medium only.…”

Section: Methodsmentioning

confidence: 99%

The nature and combination of subunits used in epitope-based Schistosoma japonicum vaccine formulations affect their efficacy

et al. 2010

View full text Add to dashboard Cite

BackgroundSchistosomiasis remains a major public health problem in endemic countries and is caused by infections with any one of three primary schistosome species. Although there are no vaccines available to date, this strategy appears feasible since natural immunity develops in individuals suffering from repeated infection during a lifetime. Since vaccinations resulting in both Th1- and Th2-type responses have been shown to contribute to protective immunity, a vaccine formulation with the capacity for stimulating multiple arms of the immune response will likely be the most effective. Previously we developed partially protective, single Th- and B cell-epitope-based peptide-DNA dual vaccines (PDDV) (T3-PDDV and B3-PDDV, respectively) capable of eliciting immune responses against the Schistosoma japonicum 22.6 kDa tegument antigen (Sj22.6) and a 62 kDa fragment of myosin (Sj62), respectively.ResultsIn this study, we developed PDDV cocktails containing multiple epitopes of S. japonicum from Sj22.6, Sj62 and Sj97 antigens by predicting cytotoxic, helper, and B-cell epitopes, and evaluated vaccine potential in vivo. Results showed that mice immunized with a single-epitope PDDV elicited either Tc, Th, or B cell responses, respectively, and mice immunized with either the T3- or B3- single-epitope PDDV formulation were partially protected against infection. However, mice immunized with a multicomponent (3 PDDV components) formulation elicited variable immune responses that were less immunoprotective than single-epitope PDDV formulations.ConclusionsOur data show that combining these different antigens did not result in a more effective vaccine formulation when compared to each component administered individually, and further suggest that immune interference resulting from immunizations with antigenically distinct vaccine targets may be an important consideration in the development of multicomponent vaccine preparations.

show abstract

“…Single epitope-based DNA vaccines can elicit specific immune responses against T-or B-cell epitopes in mice [22] . In addition, a vaccine based on a single epitope vaccine may avoid the problems of inaccurate cleavage and conformational presentation sometimes seen in vaccines encoding multiple epitopes.…”

Section: Discussionmentioning

confidence: 99%

Towards a Novel Vaccine against Human Cytomegalovirus Based on a Chimeric Ad5F35 Adenovirus Vector Expressing the Immunodominant Antigenic Domain 1 Epitope

Zhao

Yan

et al. 2009

Intervirology

View full text Add to dashboard Cite

Background: Antibodies induced from glycoprotein B (gB) by antigenic domain (AD)-1 demonstrate broad neutralizing activity across different human cytomegalovirus (HCMV) types. This study aimed to prepare a novel HCMV vaccine using the modified adenoviral vector Ad5F35 to direct the expression of the conserved HCMV epitope AD-1 and to determine its transfer and expression in peripheral blood mononuclear cells (PBMCs). Methods: AD-1 genes were amplified from AD169 HCMV strain and cloned into the Ad5F35 vector. Ad5F35-AD-1 virus vaccine was prepared by packaging Ad5F35-AD-1 into HEK293 cells. RT-PCR and fluorescence detection were used to detect the expression of AD-1 in HEK293 cells. PBMCs were stimulated in vitro with Ad5F35-AD-1 virus vaccine. The AD-1 expression in PBMCs was determined with immunocytochemistry and cell viability was measured to observe the possible adverse effects of AD-1 on PBMCs. Results: We constructed an Ad5F35-AD-1 vector and transferred it into HEK293 cells to prepare the Ad5F35-AD-1 virus vaccine successfully. The AD-1 gene was proved to be expressed in HEK293 cells. In vitro stimulation of PBMCs with Ad5F35-AD-1 showed the highly efficient expression of AD-1 and low cytopathic activity in PBMCs. Conclusion: The novel vaccine Ad5F35-AD-1 is a promising candidate for clinical trials and may be of utility in prime-boost strategies for HCMV prevention and control.

show abstract

Single B or T-cell epitope-based DNA vaccine using modified vector induces specific immune response against hepadnavirus

Cited by 4 publications

References 36 publications

A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection

A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection

The nature and combination of subunits used in epitope-based Schistosoma japonicum vaccine formulations affect their efficacy

Towards a Novel Vaccine against Human Cytomegalovirus Based on a Chimeric Ad5F35 Adenovirus Vector Expressing the Immunodominant Antigenic Domain 1 Epitope

Contact Info

Product

Resources

About